Cargando…
Chimeric Antigen Receptor Therapy for B-cell Malignancies
We presented data showing that the CART-19 cells expressing the 4-1BB signaling domain can have unprecedented and massive in-vivo expansion, traffic to tumor sites, persist long term in vivo, and induce rapid and potent anti-tumor activity in chemotherapy refractory CLL patients.
Autores principales: | Porter, David L, Kalos, Michael, Zheng, Zhaohui, Levine, Bruce, June, Carl |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3119397/ https://www.ncbi.nlm.nih.gov/pubmed/21716851 |
Ejemplares similares
-
Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
por: Kalos, Michael
Publicado: (2016) -
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018) -
Chimeric antigen receptor T‑cell therapy—a hematological success story
por: Wohlfarth, Philipp, et al.
Publicado: (2018) -
Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019) -
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
por: Uslu, Ugur, et al.
Publicado: (2023)